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INTRODUCTION: B-type or Brain natriuretic peptide (BNP) was first isolated 
from the porcine brain, but it is primarily secreted from the cardiac 
ventricles in humans. As a cardiac hormone it has a physiologic regulatory 
function in the cardiovascular system. Along with atrial, and C-type 
natriuretic peptides, BNP aids in the natriuretic, diuretic, and vasorelaxant 
responses intended to reduce blood pressure and fluid volume homeostasis. Its 
vasodilator properties are known to be present in the pulmonary circulation; 
therefore, we hypothesized that BNP can be used as a therapy to lower the 
pulmonary artery pressure in an animal model of pulmonary hypertension.  
 
METHODS: Male Sprague-Dawley rats were given a one-time subcutaneous 
injection of 60 mg/kg monocrotaline to induce PH over a five week period. 
After establishment of PH, rats were anesthetized and ventilated. A catheter 
was placed in the right jugular vein and passed into the right ventricle to 
record right ventricular pressure (RVSP), an estimate of pulmonary artery 
pressure. A second catheter was placed in the right carotid artery to measure 
mean arterial pressure (MAP). RVSP and MAP were recorded before, during, and 
after infusions of BNP.  
 
RESULTS: One hour infusions of 5, 25, 50 or 150 ng/kg min BNP caused 24, 31 
38, or 36% decreases in RVSP, respectively. There was no evidence of systemic 
hypotension at these doses of BNP.  
 
CONCLUSION: These preliminary findings suggest that BNP causes dose dependent 
decreases in pulmonary artery pressure in rats with pulmonary hypertension. 
Further study is needed to confirm these preliminary results. 
